Theratechnologies Stock Performance
| TH Stock | CAD 2.26 0.05 2.16% |
The entity has a beta of 1.08, which indicates a somewhat significant risk relative to the market. Theratechnologies returns are very sensitive to returns on the market. As the market goes up or down, Theratechnologies is expected to follow. At this point, Theratechnologies has a negative expected return of -0.0052%. Please make sure to validate Theratechnologies' maximum drawdown, as well as the relationship between the accumulation distribution and market facilitation index , to decide if Theratechnologies performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Theratechnologies has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, Theratechnologies is not utilizing all of its potentials. The newest stock price disarray, may contribute to short-term losses for the investors. ...more
| Begin Period Cash Flow | 34.1 M |
Theratechnologies |
Theratechnologies Relative Risk vs. Return Landscape
If you would invest 240.00 in Theratechnologies on December 19, 2024 and sell it today you would lose (14.00) from holding Theratechnologies or give up 5.83% of portfolio value over 90 days. Theratechnologies is currently producing negative expected returns and takes up 4.3267% volatility of returns over 90 trading days. Put another way, 38% of traded stocks are less volatile than Theratechnologies, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Theratechnologies Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Theratechnologies' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Theratechnologies, and traders can use it to determine the average amount a Theratechnologies' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0012
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | TH |
Estimated Market Risk
| 4.33 actual daily | 38 62% of assets are more volatile |
Expected Return
| -0.01 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.0 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Theratechnologies is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Theratechnologies by adding Theratechnologies to a well-diversified portfolio.
Theratechnologies Fundamentals Growth
Theratechnologies Stock prices reflect investors' perceptions of the future prospects and financial health of Theratechnologies, and Theratechnologies fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Theratechnologies Stock performance.
| Return On Equity | -11.17 | ||||
| Return On Asset | 0.0779 | ||||
| Profit Margin | (0.1) % | ||||
| Operating Margin | 0.04 % | ||||
| Current Valuation | 158 M | ||||
| Shares Outstanding | 45.98 M | ||||
| Price To Earning | (52.28) X | ||||
| Price To Book | 19.46 X | ||||
| Price To Sales | 1.24 X | ||||
| Revenue | 85.87 M | ||||
| EBITDA | 10.6 M | ||||
| Cash And Equivalents | 9.21 M | ||||
| Cash Per Share | 0.35 X | ||||
| Total Debt | 3.49 M | ||||
| Debt To Equity | 6.46 % | ||||
| Book Value Per Share | (0.55) X | ||||
| Cash Flow From Operations | 2.38 M | ||||
| Earnings Per Share | (0.24) X | ||||
| Total Asset | 53.34 M | ||||
| Retained Earnings | (416.89 M) | ||||
| Current Asset | 34.42 M | ||||
| Current Liabilities | 16.85 M | ||||
About Theratechnologies Performance
By examining Theratechnologies' fundamental ratios, stakeholders can obtain critical insights into Theratechnologies' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Theratechnologies is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Theratechnologies Inc., a biopharmaceutical company, markets prescription products in the United States, Europe, and Canada. The company was founded in 1993 and is headquartered in Montreal, Canada. THERATECHNOLOGIES operates under Drug ManufacturersSpecialty Generic classification in Canada and is traded on Toronto Stock Exchange. It employs 42 people.Things to note about Theratechnologies performance evaluation
Checking the ongoing alerts about Theratechnologies for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Theratechnologies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Theratechnologies generated a negative expected return over the last 90 days | |
| Theratechnologies has high historical volatility and very poor performance | |
| The company reported the revenue of 85.87 M. Net Loss for the year was (8.31 M) with profit before overhead, payroll, taxes, and interest of 65.42 M. |
- Analyzing Theratechnologies' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Theratechnologies' stock is overvalued or undervalued compared to its peers.
- Examining Theratechnologies' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Theratechnologies' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Theratechnologies' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Theratechnologies' stock. These opinions can provide insight into Theratechnologies' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Theratechnologies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Theratechnologies Stock, please use our How to Invest in Theratechnologies guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.